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Methylenetetrahydrofolate reductase gene (MTHFR) C677T polymorphism may be a risk factor 
for head and neck squamous cell carcinoma due to changes in folate levels that can induce disorders 
in the methylation pathway, which results in carcinogenesis. 
Aim: To evaluate MTHFR C677T polymorphism in patients with head and neck squamous cell 
carcinoma and in individuals with no history of cancer, and to assess the association of this disease 
with clinical histopathological parameters. 
Series and Methods: A retrospective study that assessed gender, age, tobacco, alcohol consumption 
and clinical histopathological parameters in 200 patients (100 with disease and 100 with no history 
of cancer). PCR-RFLP molecular analysis was carried out and the chi-square test and multiple logistic 
regression were applied for the statistical analysis. 
Results: There was no association between MTHFR C677T polymorphism and head and neck 
cancer (p = 0.50). Significant differences between the study and control groups were observed at 
age over 50 years, tobacco use, and male gender (p <0.001). There was no association of disease 
with clinical-histopathological parameters. 
Conclusion: No association between the MTHFR C677T polymorphism and head and neck squamous 
cell carcinoma was possible in this study.
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INTRODUCTION
Head and neck squamous cell carcinoma is one 
of the five most common types of cancer worldwide. It 
is sixth in cancer mortality and comprises cancers of the 
mouth (40%), pharynx (15%), and larynx (25%).1
Head and neck squamous cell carcinoma patients 
are generally diagnosed at a late stage of the disease; 
about 75% of cases are diagnoses in stages III or IV. The 
situation is worse in developing countries, such as India, 
Thailand and Brazil,3 where this cancer is more common.4 
The mean survival rate in these patients is 5 years.5 The 
5-year life expectancy is about 50% when there are lym-
ph node metastases.6,7 No significant increase in survival 
rates had occurred in the last few decades in spite of 
new surgical techniques, radiotherapy and concomitant 
chemotherapy.4,5,6,8
Epidemiologic studies have suggested a multifactor 
etiology for this cancer; these predisposing factors inclu-
de smoking, alcohol use, human papilloma virus (HPV) 
infection, and genetic factors.1,4,7,9,10
Genetic polymorphisms leading to folate deficiency 
appear to facilitate the onset and growth of head and neck 
squamous cell carcinoma and other types of cancer. Fo-
late is part of DNA methylation, in which methyl groups 
(CH3) are transferred to the 5’ position of cytosine residues 
on cytosine-guanine (CpG) dinucleotides in reactions 
catalyzed by proteins (DNA methyltransferases).11 This 
epigenetic modification of DNA has several functions, such 
as controlling gene expression, stabilizing the chromatin 
structure, and maintaining genomic stability.11-22
C677T polymorphism of the methyenetetrahydrofo-
late reductase (MTHFR) gene appears to be related with 
cancer susceptibility because the activity of the MTHFR 
enzyme (which is part of folate metabolism) is reduced; 
this may cause uncontrolled gene expression, genomic 
instability, and induce carcinogenesis.23,24
Because of the significant ethnic and geographic va-
riation in the frequency of the C677T variant of the MTHFR 
gene, researchers have evaluated the Hardy-Weinberg 
equilibrium of this gene in different populations to study 
whether allele frequencies remain unaltered across gene-
rations. Jim et al.’s meta-analysis (2009)25 investigated five 
Asian and five European or American ethnic populations 
and confirmed that the genotype  distribution in the control 
group in two studies did not abide by the Hardy-Weinberg 
principle. Studies by Suzuki et al. (2007),15 Solomon et 
al. (2008),26 and Kruszyna et al. (2009),27 respectively in 
Asian, Polish and Indian populations, found that genotype 
frequencies were in Hardy-Weinberg equilibrium.
Based on current evidence, the purpose of this 
study was to identify MTHFR C677T polymorphism in 
patients with head and neck squamous cell carcinoma and 
in subjects with no history of cancer, and to investigate 
associations between this polymorphism, clinical findin-
gs, demographic data (age and gender) and risk factors 
(smoking habits and alcohol consumption) in this disease.
SERIES AND METHODS
The institutional review board of the institution 
approved this study (number 5566/2005).
There were 200 subjects in this study; 100 (84 male 
and 16 female; mean age - 59.05 ± 10.4 years) were pa-
tients with a histopathologic diagnosis of head and neck 
squamous cell carcinoma, seen at a university hospital in 
the Northeastern part of São Paulo state, and 100 other 
subjects (76 male and 24 female; mean age - 43.61 ± 2.2 
years) that had no medical history of cancer. Subjects 
were included in the study after signing a free informed 
consent form.
The control group included individuals from the 
blood bank of São José de Rio Preto, with no diagnosis of 
cancer according to the blood donor protocol that asses-
ses 20 diseases (http://www.hemonline.com.br/portarias/
rdc153/indexframe.htm). Another inclusion criterion was 
age over 40 years; exclusion criteria were a family history 
of cancer and the presence of any disease in the blood do-
nor protocol. The study group consisted of patients with a 
diagnosis of head and neck carcinoma based on pathology 
specimens from biopsies or total excision. The inclusion 
criterion was patients with the squamous cell histological 
type; previously treated patients were excluded.
The study variables were age, gender, exposure to 
risk factors (alcohol consumption and cigarette smoking), 
and tumor-related clinical parameters. Smokers were 
defined here as subjects that had smoked about 100 ciga-
rettes in their lives, and alcohol consumers were subjects 
that drank more than four drinks a week.28,29 The clinical 
parameters included the primary sites of tumors (mouth, 
pharynx and larynx); tumors were classified according to 
the parameters issued by the Union International Control 
Cancer (IUCC), 2002, and the American Joint Committee 
for Cancer (AJCC), 2002, as follows: tumor size (T), and 
presence of involved regional lymph nodes (N). Clinical 
and pathology data were gathered from medical registries.
Extracted genomic DNA, according to Miller et al. 
(1998), modified,30 was PCR-amplified, according to Yi et 
al., 2002.31 The amplification product was digested with the 
Hinf I restriction enzyme according to the manufacturer’s 
instructions, to detect the polymorphic site (MTHFR 677T).
The multiple logistic regression model was applied 
to evaluate the effect of variables and the genotype distri-
bution among groups. The model included the following 
variables: age (reference: age below the median in both 
groups), gender (reference: female sex), smoking habits 
(reference: non-smokers); alcohol consumption (reference: 
non-drinkers).
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Multiple logistic regression was also applied to 
analyze the clinical features and pathology. The T classi-
fication was the same in small (T1, T2) and large tumors 
(T3, T4). The N classification was separated into negative 
(N0) and positive lymph node involvement (N1, N2, N3).
Results are presented as odds ratio (OR) and 95% 
confidence intervals (CI - 95%). The significance level was 
5% (p=0.05). The Bioestat and Instat software packages 
were used in the statistical analysis.
RESULTS
Table 1 presents the social and demographic data of 
100 patients with head and neck squamous cell head and 
neck squamous cell carcinoma and of 100 subjects with 
no history of cancer. There were significant differences 
between the study and control groups at ages over 50 
years, smoking habits, and male gender (p < 0.001). There 
were 160 male subjects (80%; 84 patients and 76 controls) 
and 40 female subjects (20%; 16 patients and 24 controls). 
Smokers comprised 88% of the study group, compared 
to 43% in the control group. Alcohol consumers were 
77% of the study group and 49% of controls. There was 
no significant difference between these groups (p=0.06).
The Hardy-Weinberg equilibrium showed that ge-
notype distributions were similar to those expected among 
patients (X2 = 1.18; p = 0.23) and in controls (X2 = 0.23; 
p = 0.63). The genotype CC, CT and CC frequencies of 
the C677T polymorphism were respectively 44%, 43% and 
13% for patients, and 46%, 40% and 14% in controls. There 
were no significant differences in genotype distribution 
between groups (p= 0.92).
The allele frequencies for head and neck cancer 
patients were respectively, C=0.65 and T=0.35, and for 
controls C=0.66 and T=0.34. There were no statistically 
significant differences between groups (p=1.00).
The multiple logistic regression test was applied to 
evaluate the effect of variables on disease progression (ge-
notypes, age, gender, smoking and alcohol consumption) 
(see Table 1). Age over 50 years (OR = 20.81; CI= 9.01 to 
48,09; p < 0.0001) and smoking (OR= 5.03; CI =1.93 to 
13.15; p < 0.001) were predictors of disease.
Polymorphism was not associated with primary 
tumor sites (mouth, pharynx and larynx), tumor exten-
sion, and lymph node involvement. Primary sites were 
the mouth (34% of patients), the larynx (31%), and the 
larynx (22%). The remaining sites were unknown. The 
TNM classification was stages T1 or T2 in 59% of patients 
- of which 34,6% had the CC wild genotype, and 65.4% 
had at least one mutated allele (CT or TT genotypes). The 
remaining patients (41%) were stages T3 or T4, of which 
55% had the CC wild genotype, and 45% had at least one 
mutated allele (CT or TT genotypes). Lymph nodes were 
involved (N+) in 26.6% of patients (37.5% with the CC 
Table 1. Distribution of demographic data, risk factors, MTHFR C677T genotype and the odds ratio (OR) patients with head and neck squa-
mous cell carcinoma and subjects with no history of cancer
Variables Patients (n = 100) % Controls (n = 100) % OR (IC 95%) p
Age     
mean (years) 59,05 43,61  
< 0.001< 50 years 19 79 Reference
> 50 years 81 21 20,81 (9.01-48.09)
Gender     
Female 16 24 Reference
0,02
Male 84 76 0,27 (0.09-0.82)
Smoking     
No 88 43 Reference
0,001
Yes 12 57 5,03 (1.93-13.15)
Alcohol consumption     
No 23 51 Reference  
0,06Yes 77 49 2,38 (0.94-6.05)
C677T polymorphism     
CC 44 46 Reference
0,50
CT/TT 43/13 40/14 1,31 (0,59-2,93)
*Adjusted for age, gender, tobacco and alcohol consumption (multiple logistic regression). There were statistically significant differences among 
groups for age over 50 years, male gender, and tobacco and alcohol consumption.
Smokers were subjects that consumed up to 5 cigarettes a day. Alcohol consumers were subjects that consumed on average up to 4 drinks a 
week (multiple logistic regression).
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genotype, and 62.5% with at least one mutated allele - CT 
or TT genotypes).
DISCUSSION
This study showed that head and neck squamous 
cell carcinoma is more frequent in smokers aged over 50 
years. Published results have also shown that this can-
cer is more frequent after the fifth decade of life and in 
smokers.32-34
No relationship between alcohol consumption and 
head and neck squamous cell carcinoma was found, such 
as in the study by Boccia et al. (2009).35 Animal studies have 
suggested that alcohol is not genotoxic, but that it may act 
as a solvent for the entry of carcinogens. Acetaldehyde, 
the primary metabolite of alcohol, is highly reactive and 
binds to proteins, cells substrates, and DNA, forming DNA 
adducts.36-38 Excessive alcohol consumption may also lead 
to nutritional deficiencies because of impaired intestinal 
absorption and altered metabolic pathways.39 The results 
of a multicenter study have suggested that in the absence 
of smoking, the association between alcohol consumption 
and head and neck carcinoma is insignificant; alcohol 
appears to be carcinogenic only at high doses.40
We found no association between gender and this 
disease in our series; other studies, however, have found 
this association and have suggested that the incidence of 
this disease in females has increased in the past few deca-
des. Males are still  more affected by this type of tumor.41,42
MTHFR C677T polymorphism has been studied as 
a risk factor for cancer susceptibility because of its effect 
on cell methylation reactions and DNA synthesis. Global 
genome hypomethylation occurs with greater frequency 
in tumors compared to normal cells; it is thought that 
increased oncogene expression by result from hypome-
thylation. On the other hand, hypermethylation of CpG 
islands located in gene promoting regions has been as-
sociated with altered gene expression, resulting in tumor 
suppressing gene silencing.43
The genotype frequencies in our study were in 
Hardy-Weinberg equilibrium. The polymorphic genotype 
(MTHFR 677TT) was found in 14% of controls and 13% 
of patients with head and neck squamous cell carcinoma. 
There is considerable ethnic and geographic variation in 
Table 2. Distribution of clinical and pathology parameters and MTHFR C677T polymorphism 
Clinical findings*/ Genotypes Frequency OR (IC 95%) p
Mouth   
0,51MTHFR CC 14 Reference
MTHFR CT/TT 22 1,46 (0,47-4,55)
Pharynx   
0,52MTHFR CC 11 Reference
MTHFR CC/TT 11 0,722 (0,27-1,96)
Larynx   
0,96MTHFR CC 14 Reference
MTHFR CT/TT 17 1,02 (0,43-2,44)
T1 e T2   
0,08
MTHFR CC 17 Reference
MTHFR CT/TT 32
T3 e T4   
MTHFR CC 19 0,45 (0,19-1,10)
MTHFR CT/TT 15
N0   
0,62
MTHFR CC 29 Reference
MTHFR CT/TT 37
N+   
MTHFR CC 9 1,36 (0,39-4,78)
MTHFR CT/TT 15
*Only tumors of the mouth, pharynx, and larynx were considered. The analysis was made only of patients with complete registries.
MTHFR CT or TT genotypes compared with clinical parameters. Reference: MTHFR CC (multiple logistic regression)
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the frequency of the C677T variant of the MTHFR gene. 
The prevalence of the MTHFR 677TT genotype ranges from 
1% in blacks (US, Africa and South America) to over 20% 
in Europeans, Colombians, and American Indians; 12% of 
Japanese were TT homozygotes.44 Because of the ample 
mixture of races in the Brazilian population, no analysis 
of ethnic prevalence were made in our series.
We found no association between MTHFR C677T 
polymorphism and head and neck carcinoma in our se-
ries. Other studies have shown an association between 
this polymorphism and several cancers, such as those 
of the lung45,35 liver (hepatocellular carcinoma),46 a few 
leukemias,47 prostate cancer,48 breast,49 colon,49 endome-
trium, esophagus, stomach, pancreas, and bladder.46 A 
meta-analysis of nine head and neck carcinoma studies 
found no association between this polymorphism and this 
disease, which concurs with our results.32 However, Reljic 
et al. (2007)50 and Solomon et al. (2008)26 found that head 
and neck carcinoma and the MTHFR C677T polymorphism 
were associated in Croat and Indian populations.
Reljic et al. (2007)50 studied 81 patients with head 
and neck carcinoma and 102 controls, and found a statis-
tically significant difference in the genotype distribution 
of both groups, which provides evidence of a possible 
association between MTHFR C677T polymorphism and 
head and neck carcinoma. This analysis revealed that the 
677CT genotype reduces the risk of this disease by 2.8 
times. Solomon et al. (2008)26 studied 126 Indian subjects 
with mouth carcinoma (33 were alcohol consumers, 56 
were moderate alcohol consumers, and 37 did not con-
sume alcohol) and showed that alcohol consumers with 
the MTHFR 677TT genotype were at a higher risk for de-
veloping mouth carcinoma (OR - 3.0; 95% CI = 2.02-4.0) 
and that the TT genotype protected only non-alcohol and 
moderate alcohol consumers.
There are no published studies describing abnor-
malities of the gene above and head and neck squamous 
cell carcinoma in Brazil; although our results were not 
statistically significant, it is interesting to study these 
abnormalities because of contradictory results and the 
paucity of studies.
The most frequent tumor site was the mouth - 40% 
of head and neck cancers.51,52 In the TNM classification, 
19% of cases were stage T1, 30% were stage T2, 17% were 
stage T3, and 17% were stage T4. Lymph nodes were not 
involved in 73.4% of patients, and there were no metastases 
in 99% of cases. A retrospective Brazilian study revealed a 
high frequency of this disease at advanced stages.53 This 
discrepancy with our findings appears to reflect the type 
of study population; in our case, monitored patients.
MTHFR C677T polymorphism was not associated 
with the clinical parameters of this study (primary tumor 
sites, tumor extension, and lymph node involvement). 
Capaccio et al.54 (20050 studied the presence of this poly-
morphism in several oropharyngeal anatomical sites and 
found no association among the abovementioned varia-
bles. There was no association between this polymorphism 
and disease extension (T stage) and tumor staging in the 
three regions of the head and neck (mouth, pharynx, 
and larynx) when analyzing tumor aggressiveness, which 
concurs with Vairaktaris et al.’s (2006) study.55
CONCLUSION
To conclude, no associations were found between 
MTHFR C677T polymorphism and head and neck squa-
mous cell carcinoma. Our data showed that the frequency 
of this disease is higher after the fifth decade of life 
and in smokers. Clarifying any association between this 
polymorphism and head and neck carcinoma - and the 
association of this cancer type with other risk factors - will 
help understand the neoplastic mechanisms underlying 
this disease, as well as prevention and control measures.
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